FDA is expanding its Emerging Technology Program and providing more support for new drug applications that present advanced manufacturing technologies.
Jill Wechsler
Advertisement
Jill Wechsler is BioPharm International's Washington Editor, [email protected].
Articles by Jill Wechsler
Experts fear confusion over allocation processes, cold-chain requirements, and IT systems needed to bring a COVID-19 vaccine to market.
Regulators strive to review flood of advanced treatments while also vetting COVID-19 vaccines.
FDA announced it had issued an emergency use authorization for convalescent plasma that would make it easier to provide this treatment to COVID-19 patients.
Problems in assuring reliable drug quality and supply dampens progress in bringing lifesaving therapies to market.
Advertisement
Latest Updated Articles
Surge in Cellular and Gene Therapies Challenges FDASeptember 2nd 2020
- COVID-19 Vaccine Distribution Raises Multiple Challenges
November 2nd 2020
- FDA Caught in Political Crossfire
August 24th 2020
- FDA Highlights Value and Challenges of Advanced Drug Manufacturing
October 21st 2021
- Quality Issues Offset Biomedical Advances
December 2nd 2019
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Updates Master Protocol: What Developers Need to Know
2
Pharma Fundamentals: Hold Times in Biopharmaceuticals
3
Merck KGaA Launches Saturnus Bio; Announces Awards
4
IPEC’s Excipient Information Package: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires
5